These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35123559)

  • 1. Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.
    Shirazi FM; Mirzaei R; Nakhaee S; Nejatian A; Ghafari S; Mehrpour O
    Eur J Med Res; 2022 Feb; 27(1):21. PubMed ID: 35123559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
    Peña-Silva R; Duffull SB; Steer AC; Jaramillo-Rincon SX; Gwee A; Zhu X
    Br J Clin Pharmacol; 2021 Mar; 87(3):1589-1590. PubMed ID: 32779815
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.
    Cobos-Campos R; Apiñaniz A; Parraza N; Cordero J; García S; Orruño E
    Curr Res Transl Med; 2021 Oct; 69(4):103309. PubMed ID: 34418758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?
    Mittal N; Mittal R
    Med Hypotheses; 2021 Jan; 146():110364. PubMed ID: 33246694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
    Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH
    Front Immunol; 2021; 12():663586. PubMed ID: 33859652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.
    Chaudhry MW; Zubair SM; Zubairi ABS; Irfan M
    Adv Respir Med; 2021; 89(4):413-418. PubMed ID: 34494244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
    Low ZY; Yip AJW; Lal SK
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
    Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L
    J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis.
    Padhy BM; Mohanty RR; Das S; Meher BR
    J Pharm Pharm Sci; 2020; 23():462-469. PubMed ID: 33227231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
    Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
    J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
    Kinobe RT; Owens L
    Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.
    Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Rashad A; Hassan RG; Abdelmaksoud AA
    Int J Nanomedicine; 2021; 16():4063-4072. PubMed ID: 34163159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
    Okumuş N; Demirtürk N; Çetinkaya RA; Güner R; Avcı İY; Orhan S; Konya P; Şaylan B; Karalezli A; Yamanel L; Kayaaslan B; Yılmaz G; Savaşçı Ü; Eser F; Taşkın G
    BMC Infect Dis; 2021 May; 21(1):411. PubMed ID: 33947344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina.
    Chahla RE; Medina Ruiz L; Ortega ES; Morales Rn MF; Barreiro F; George A; Mancilla Rn C; D' Amato Rn S; Barrenechea G; Goroso DG; Peral de Bruno M
    Am J Ther; 2021 Aug; 28(5):e601-e604. PubMed ID: 34491960
    [No Abstract]   [Full Text] [Related]  

  • 17. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential therapeutic effects of Ivermectin in COVID-19.
    Barati N; Motavallihaghi S; Nikfar B; Chaichian S; Momtazi-Borojeni AA
    Exp Biol Med (Maywood); 2022 Aug; 247(15):1388-1396. PubMed ID: 35686662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols.
    Marques LLM; Beneti SC; Pinzon C; Cardoso FAR
    Braz J Biol; 2022; 84():e258325. PubMed ID: 35584459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.